PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.16%
R&D change of 10.16% versus flat Biotechnology spending. Walter Schloss would verify adequacy.
23.98%
G&A change of 23.98% versus flat Biotechnology overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
7.46%
Other expenses change of 7.46% versus flat Biotechnology costs. Walter Schloss would verify efficiency.
15.26%
Operating expenses growth exceeding 1.5x Biotechnology median of 0.12%. Jim Chanos would check for waste.
15.26%
Total costs growth exceeding 1.5x Biotechnology median of 0.40%. Jim Chanos would check for waste.
-36.68%
Interest expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
7.46%
D&A change of 7.46% versus flat Biotechnology D&A. Walter Schloss would verify adequacy.
-50.67%
EBITDA decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-15.26%
Operating income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-81.62%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-50.43%
Pre-tax income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-36.68%
Tax expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-50.43%
Net income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-43.14%
EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
-43.14%
Diluted EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
5.01%
Share count reduction below 50% of Biotechnology median of 0.05%. Jim Chanos would check for issues.
5.01%
Diluted share reduction below 50% of Biotechnology median of 0.06%. Jim Chanos would check for issues.